NO20064989L - Sulfonamidforbindelser for behandling av neurodegenerative lidelser - Google Patents

Sulfonamidforbindelser for behandling av neurodegenerative lidelser

Info

Publication number
NO20064989L
NO20064989L NO20064989A NO20064989A NO20064989L NO 20064989 L NO20064989 L NO 20064989L NO 20064989 A NO20064989 A NO 20064989A NO 20064989 A NO20064989 A NO 20064989A NO 20064989 L NO20064989 L NO 20064989L
Authority
NO
Norway
Prior art keywords
treatment
neurodegenerative disorders
sulfonamide compounds
compounds
formula
Prior art date
Application number
NO20064989A
Other languages
English (en)
Inventor
Michael Aaron Brodney
Karen Jean Coffman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20064989L publication Critical patent/NO20064989L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I) hvori R1, R2, R3, m, og n er som definert. Forbindelser med formel (I) har aktivitet som inhiberer produksjon av Aß-peptid. Oppfinnelsen angår også farmasøytiske sammensetninger og fremgangsmåter for behandling av forstyrrelser og sykdommer, for eksempel, neurodegenerative og/eller neurologiske forstyrrelser, for eksempel, Alzheimers sykdom, hos et pattedyr som innbefatter forbindelser med formel (I).
NO20064989A 2004-04-01 2006-10-31 Sulfonamidforbindelser for behandling av neurodegenerative lidelser NO20064989L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55866004P 2004-04-01 2004-04-01
PCT/IB2005/000796 WO2005095334A1 (en) 2004-04-01 2005-03-21 Sulfonamide compounds for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
NO20064989L true NO20064989L (no) 2007-01-02

Family

ID=34962303

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064989A NO20064989L (no) 2004-04-01 2006-10-31 Sulfonamidforbindelser for behandling av neurodegenerative lidelser

Country Status (28)

Country Link
US (2) US7163942B2 (no)
EP (1) EP1747195A1 (no)
JP (2) JP2007530660A (no)
KR (1) KR20060130705A (no)
CN (1) CN1938266A (no)
AP (1) AP2006003729A0 (no)
AR (1) AR048348A1 (no)
AU (1) AU2005227749A1 (no)
BR (1) BRPI0509477A (no)
CA (1) CA2562114A1 (no)
CR (1) CR8669A (no)
DO (1) DOP2005000049A (no)
EA (1) EA200601607A1 (no)
EC (1) ECSP066888A (no)
GT (1) GT200500070A (no)
IL (1) IL177955A0 (no)
MA (1) MA28493B1 (no)
MX (1) MXPA06011348A (no)
MY (1) MY136718A (no)
NL (1) NL1028664C2 (no)
NO (1) NO20064989L (no)
PE (1) PE20060147A1 (no)
SV (1) SV2006002073A (no)
TN (1) TNSN06314A1 (no)
TW (1) TW200602297A (no)
UY (1) UY28825A1 (no)
WO (1) WO2005095334A1 (no)
ZA (1) ZA200607213B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005927A (es) 2001-12-20 2004-11-01 Squibb Bristol Myers Co Derivados de alfa-(n-sulfonamido)acetamida como inhibidores del peptido beta-amiloideo.
RS50595B (sr) * 2004-03-23 2010-05-07 Pfizer Products Incorporated Jedinjenja imidazola za lečenje neurodegenerativnih poremećaja
EP1940802A2 (en) * 2005-09-22 2008-07-09 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
BRPI0808348A2 (pt) * 2007-03-05 2014-07-15 Hoffmann La Roche Aminoamidas como antagonistas de orexina
CN102088855A (zh) * 2008-05-08 2011-06-08 百时美施贵宝公司 2-芳基甘氨酰胺衍生物
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2012162249A1 (en) * 2011-05-20 2012-11-29 Benjamin Wolozin Identification of compounds that disperse tdp-43 inclusions
WO2013026021A2 (en) * 2011-08-18 2013-02-21 Buck Institute For Research On Aging Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease
CN107722012B (zh) 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS484784U (no) * 1971-06-16 1973-01-19
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5491170A (en) * 1994-12-19 1996-02-13 Warner-Lambert Company β-carboxy sulfonamide ACAT inhibitors
EP0967201A1 (en) 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
WO2003051825A1 (en) 2001-12-14 2003-06-26 Exelixis, Inc. Human adam-10 inhibitors
MXPA04005927A (es) 2001-12-20 2004-11-01 Squibb Bristol Myers Co Derivados de alfa-(n-sulfonamido)acetamida como inhibidores del peptido beta-amiloideo.

Also Published As

Publication number Publication date
US7163942B2 (en) 2007-01-16
MY136718A (en) 2008-11-28
UY28825A1 (es) 2005-10-31
JP2008189673A (ja) 2008-08-21
NL1028664C2 (nl) 2006-03-22
WO2005095334A1 (en) 2005-10-13
CA2562114A1 (en) 2005-10-13
CR8669A (es) 2006-11-01
ZA200607213B (en) 2008-04-30
AR048348A1 (es) 2006-04-19
BRPI0509477A (pt) 2007-09-11
NL1028664A1 (nl) 2005-10-05
CN1938266A (zh) 2007-03-28
AU2005227749A1 (en) 2005-10-13
AP2006003729A0 (en) 2006-10-31
EA200601607A1 (ru) 2007-02-27
US20050222254A1 (en) 2005-10-06
TNSN06314A1 (fr) 2007-12-03
US7345095B2 (en) 2008-03-18
DOP2005000049A (es) 2005-12-15
KR20060130705A (ko) 2006-12-19
PE20060147A1 (es) 2006-03-08
MA28493B1 (fr) 2007-03-01
JP2007530660A (ja) 2007-11-01
MXPA06011348A (es) 2006-12-15
SV2006002073A (es) 2006-05-09
IL177955A0 (en) 2006-12-31
TW200602297A (en) 2006-01-16
EP1747195A1 (en) 2007-01-31
US20070129349A1 (en) 2007-06-07
GT200500070A (es) 2005-10-31
ECSP066888A (es) 2006-11-24

Similar Documents

Publication Publication Date Title
NO20064989L (no) Sulfonamidforbindelser for behandling av neurodegenerative lidelser
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
NO20052223L (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
CA2534532A1 (en) Compounds for the treatment of neurodegenerative disorders
MXPA05012196A (es) Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
WO2005097114A3 (en) Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
NO20081845L (no) Imidazolforbindelser for behandling av neurologiske lidelser
NO20070665L (no) Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
EA201070367A1 (ru) Производное 6-пиримидинилпиримид-4-она
DE602004010314D1 (de) Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren
BRPI0509582A (pt) compostos de tiazol-amina e respectivas composições farmacêuticas
CA2534529A1 (en) Oxazole compounds for the treatment of neurodegenerative disorders
NO20090814L (no) N-fenyl-prenylamin derivater for behandling av kognitive, neurodegenerative eller neurone sykdommer eller lidelser
WO2005095361A8 (en) Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
NO20090812L (no) Fenyl-prenyl-eter derivater for behandling av kognitive, neurodegenerative eller neurone sykdommer eller lidelser
EA200500382A1 (ru) Соединения тиазола для лечения нейродегенеративных расстройств
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos
MY145068A (en) Imidazole compounds for the treatment of neurodegenerative disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application